We disagree with the comment of Forbes regarding our misinterpretation of data from the study of Catassi et al. 1 and our statement that a safe daily limit is probably in the region of 10 mg/day. First, in the Catassi et al. study the authors reported that 'some Celiac Disease patients showed a clear-cut worsening of the small-intestinal architecture after ingesting only 10 mg gluten/day' and 1/13 patients challenged with 10 mg gluten/day developed a clinical relapse p.164. Therefore, with the limit of the small number of patients challenged with 10 mg gluten in this study (n ¼ 13) some effects have been reported also for the quantity of 10 mg/day. The Food and Drug Administration (FDA) safety analysis 2 concluded that <1 ppm of gluten in foods is required to protect the greatest number of patients. In the FDA report it is clearly specified that, in the gluten exposure studies examined, the results are not presented or interpreted within a toxicological risk assessment framework.
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Therefore, for the FDA hazard/safety analysis, the results were reinterpreted within the frame of reference of 1 ppm.
The average no observable adverse effect level and the lowest observable adverse effect level associated with morphological effects were calculated utilising the appropriate uncertainty factor (that takes into account the variability among studies and data) and indicated as tolerable the acute intake level for gluten of 12.5 mg/day, and for the subchronic exposure 0.4 mg gluten/day and for chronic exposure 7.0 mg gluten/day.
The FDA report, with the limitation of the available data, indicates as tolerable a quantity of gluten close to the one reported in our review. At the moment we do not have any reliable data for toxicity of gluten quantities in the range from 10-50 mg/day. Therefore, on the basis of the scanty data we have, according to the FDA safety assessment analysis and with the limit of personal sensitivity, the only conclusion is that 50 mg could be unsafe for most CD patients and 10 mg should be safe for most of the patients.
Our final recommendation that the CD patients should be vigilant with their diet and avoid all sources of known gluten or contamination is the only reasonable conclusion.
